References
- Agin-Liebes, G. I., T. Malone, M. M. Yalch, S. E. Mennenga, K. L. Ponte, J. Guss, A. P. Bossis, J. Grigsby, S. Fischer, and S. Ross. 2020. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology (Oxford, England) 34 (2):155–66. doi:10.1177/0269881119897615.
- Anderson, B. T., A. Danforth, R. Daroff, C. Stauffer, E. Ekman, G. Agin-Liebes, A. Trope, M.T. Boden, J. Dilley, J. Mitchell, et al. 2020. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27 (October):100538. doi:10.1016/j.eclinm.2020.100538.
- Barnett, B., Y. Beaussant, F. King IV, and R. Doblin. 2020. Psychedelic knowledge and opinions in psychiatric professional conference attendees: Survey instrument. https://doi.org/10.6084/m9.figshare.13218080.v3.
- Barnett, B. S., W. O. Siu, and H. G. Pope Jr. 2018. A survey of American psychiatrists’ attitudes toward classic Hallucinogens. The Journal of Nervous and Mental Disease 206 (6):476–80. doi:10.1097/NMD.0000000000000828.
- Beaussant, Y., J. Sanders, Z. Sager, J. A. Tulsky, I. M. Braun, C. D. Blinderman, A. P. Bossis, and I. Byock. 2020 April. Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert clinicians’ and investigators’ perspectives. Journal of Palliative Medicine 23 (10):1323–34. doi:10.1089/jpm.2019.0603.
- Begola, M. J., and J. E. Schillerstrom. 2019. Hallucinogens and their therapeutic use: A literature review. Journal of Psychiatric Practice 25 (5):334–46. doi:10.1097/PRA.0000000000000409.
- Business Wire. 2019. FDA grants breakthrough therapy designation to Usona institute’s Psilocybin program for major depressive disorder. https://www.businesswire.com/news/home/20191122005452/en/FDA-grants-Breakthrough-Therapy-Designation-Usona-Institutes.
- Calder, A. 2020. Compassionate use – psychedelic therapy for those who can’t wait. Psychedelic Science Review. https://psychedelicreview.com/compassionate-use-psychedelic-therapy-for-those-who-cant-wait/.
- Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of Psilocybin versus Escitalopram for depression. The New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
- Charuvastra, A., P. D. Friedmann, and M. D. Stein. 2005. Physician attitudes regarding the prescription of medical Marijuana. Journal of Addictive Diseases 24 (3):87–93. doi:10.1300/J069v24n03_07.
- Compass Pathways. 2018. COMPASS pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html.
- Dore, J., B. Turnipseed, S. Dwyer, A. Turnipseed, J. Andries, G. Ascani, C. Monnette, A. Huidekoper, N. Strauss, and P. Wolfson. 2019. Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs 51 (2):189–98. doi:10.1080/02791072.2019.1587556.
- Farah, T. 2020. The FDA just expanded access to MDMA as a therapy for PTSD. Vice News. https://www.vice.com/en/article/3a8dn8/the-fda-just-expanded-access-to-mdma-as-a-therapy-for-ptsd.
- Feduccia, A. 2019. How to become a psychedelic therapist. Psychedelic Support. https://psychedelic.support/resources/training-psychedelic-therapist/.
- Guss, J., R. Krause, and J. Sloshower. 2020. The Yale manual for psilocybin-assisted therapy of depression (Using acceptance and commitment therapy as a therapeutic frame). https://doi.org/10.31234/osf.io/u6v9y.
- Han-soo, L. 2020. Spravato to offer new options for treatment-resistant depression. Korea Biomedical Review. https://www.koreabiomed.com/news/articleView.html?idxno=9657.
- Harris, P. A., R. Taylor, B. L. Minor, V. Elliott, M. Fernandez, L. O’Neal, L. McLeod, G. Delacqua, F. Delacqua, J. Kirby, et al. 2019. The REDCap consortium: Building an international community of software platform partners. Journal of Biomedical Informatics 95 (July):103208. doi:10.1016/j.jbi.2019.103208.
- Harris, P. A., R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J. G. Conde. 2009. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics 42 (2):377–81. doi:10.1016/j.jbi.2008.08.010.
- Icahn School of Medicine at Mount Sinai. 2021. The center for psychedelic psychotherapy and trauma research. https://icahn.mssm.edu/research/center-psychedelic-psychotherapy-trauma-research/training-education.
- Johnson & Johnson. 2020. SPRAVATO® (Esketamine)* nasal spray is available for Canadian patients. https://www.janssen.com/canada/sites/www_janssen_com_canada/files/spravato_esketamine_nasal_spray_is_available_for_canadian_patients.pdf.
- Johnson & Johnson. 2021. SPRAVATO® (Esketamine Nasal Spray) authorised in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder. https://www.jnj.com/spravato-esketamine-nasal-spray-authorised-in-europe-for-the-rapid-reduction-of-depressive-symptoms-in-a-psychiatric-emergency-for-patients-with-major-depressive-disorder.
- Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. Human Hallucinogen research: Guidelines for safety. Journal of Psychopharmacology (Oxford, England) 22 (6):603–20. doi:10.1177/0269881108093587.
- Kondrad, E., and A. Reid. 2013. Colorado family physicians’ attitudes toward medical Marijuana. Journal of the American Board of Family Medicine : JABFM 26 (1):52–60. doi:10.3122/jabfm.2013.01.120089.
- Lekhtman, A. 2021 March. How will Oregon implement legal psilocybin therapy? Filter. https://filtermag.org/oregon-legal-psilocybin-therapy/.
- Linn, L. S., J. Yager, and B. Leake. 1989. Physicians’ attitudes toward the legalization of Marijuana use. The Western Journal of Medicine 150 (6):714–17.
- Lombardi, E., J. Gunter, and E. Tanner. 2020. Ohio physician attitudes toward medical Cannabis and Ohio’s medical Marijuana program. Journal of Cannabis Research 2 (1):16. doi:10.1186/s42238-020-00025-1.
- Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G. Marcela Ot’alora, W. Garas, C. Paleos, I. Gorman, et al. 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, Placebo-controlled phase 3 study. Nature Medicine 27 (6):1025–33. doi:10.1038/s41591-021-01336-3.
- Mithoefer, M. C. 2015. A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies. https://maps.org/research-archive/mdma/MDMA-Assisted-Psychotherapy-Treatment-Manual-Version7-19Aug15-FINAL.pdf.
- Phelps, J. 2017. Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology 57 (5):450–87. doi:10.1177/0022167817711304.
- Pollan, M. 2018. How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. London: Penguin Publishing Group.
- Reiff, C. M., E. E. Richman, C. B. Nemeroff, L. L. Carpenter, A. S. Widge, C. I. Rodriguez, N. H. Kalin, and W. M. McDonald. 2020. Psychedelics and Psychedelic-assisted psychotherapy. The American Journal of Psychiatry 177 (5):391–410. doi:10.1176/appi.ajp.2019.19010035.
- Shalit, N., J. Rehm, and S. Lev-Ran. 2019. Epidemiology of Hallucinogen use in the U.S. results from the national epidemiologic survey on alcohol and related conditions III. Addictive Behaviors 89 (February):35–43. doi:10.1016/j.addbeh.2018.09.020.
- Vijay, A., J. E. Becker, and J. S. Ross. 2018. Patterns and predictors of off-label prescription of psychiatric drugs. PloS One 13 (7):e0198363. doi:10.1371/journal.pone.0198363.
- Vollenweider, F. X., and M. Kometer. 2010. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews. Neuroscience 11 (9):642–51. England. doi:10.1038/nrn2884.